What are the recommended chemotherapy dosing regimens for pediatric medulloblastoma, including dose adjustments based on body surface area, age (including children under three), risk category, and salvage therapy for recurrence?

Chemotherapy Dosing in Pediatric Medulloblastoma

For pediatric medulloblastoma, chemotherapy dosing follows risk-stratified protocols with weekly vincristine during radiotherapy followed by maintenance chemotherapy using either COG (cisplatin/lomustine/vincristine alternating with cisplatin/cyclophosphamide/vincristine) or St. Jude protocols (vincristine/cisplatin/cyclophosphamide), with specific modifications for children under 3 years who receive chemotherapy alone without radiation. 1

Risk-Stratified Treatment Approach

Low/Average-Risk Disease

• During Radiotherapy: Weekly vincristine administered concurrently with craniospinal irradiation (23.4 Gy CSI + 54 Gy boost)
• Maintenance Chemotherapy Options:
  • COG Protocol: Alternating cycles of cisplatin/lomustine/vincristine with cisplatin/cyclophosphamide/vincristine
  • St. Jude Protocol: Vincristine/cisplatin/cyclophosphamide

These protocols are not interchangeable—once you select one, continue with that protocol's maintenance regimen 1. The COG trial (n=464) and St. Jude trial (n=330) demonstrated comparable outcomes, validating both approaches 1.

High-Risk Disease

• During Radiotherapy: Higher-dose CSI (36 Gy + 54-55.8 Gy boost) with concurrent weekly vincristine
• Maintenance Options:
  • St. Jude protocol (preferred)
  • ACNS0332 protocol: 6 cycles of cisplatin/cyclophosphamide/vincristine 1

Very High-Risk Disease (MYC Amplification, Group 3)

• Critical Addition: Carboplatin administered prior to each radiation fraction for Group 3 tumors with MYC amplification
• This radiosensitizing approach improved event-free survival by 19% in high-risk Group 3 medulloblastoma 1
• Follow with same maintenance as high-risk disease

Age-Specific Dosing Considerations

Children Under 3 Years

Radiation is NOT recommended for children <3 years due to neurotoxicity risk 1. These patients receive chemotherapy-only strategies:

Recommended Regimens:

1. Cyclophosphamide-based regimen
2. Vincristine/cisplatin/etoposide
3. Vincristine/carboplatin/temozolomide

Intensive Approach for High-Risk Cases:

• Induction: 3 cycles of vincristine/cyclophosphamide/etoposide/cisplatin every 21-28 days
• Consolidation: 3 cycles of marrow-ablative thiotepa (10 mg/kg/day × 2 days) + carboplatin with autologous hematopoietic cell rescue
• This approach achieved 5-year event-free survival of 43.9% and overall survival of 63.6% in children <3 years 2

Body Surface Area Considerations

For infants and very young children with BSA <0.6 m², dosing should use BSA dose banding tables that gradually transition from weight-based to BSA-based dosing 3. This approach reduces toxicity while maintaining efficacy.

Salvage Therapy for Recurrent Disease

Recurrent medulloblastoma carries a dismal prognosis with <10% survival rates 1. Aggressive combination systemic therapy is warranted:

First-Line Salvage Options

1. Temozolomide/Irinotecan + Bevacizumab (Preferred)

• Bevacizumab addition improved event-free survival from 6 to 9 months
• Important: Delay bevacizumab initiation if recent surgery to ensure wound healing 1

2. Temozolomide/Topotecan

• 28% overall response rate in recurrent/refractory disease
• Caveat: Expect frequent hematologic toxicities requiring close monitoring 1

3. MEMMAT Regimen (Metronomic Therapy)

• Low-dose anticancer drugs administered continuously
• Acceptable toxicity profile with promising activity in subset of patients
• Advantage: Can readminister drugs previously given at high doses 1

Critical Toxicity Monitoring

Mandatory surveillance during treatment:

• Vincristine: Monitor for peripheral neuropathy (dose-limiting)
• Cisplatin: Audiometry for ototoxicity assessment
• Carboplatin: Hematologic monitoring
• Cyclophosphamide: Hemorrhagic cystitis prevention 1

Common Pitfalls to Avoid

1. Do not mix COG and St. Jude maintenance protocols—they are distinct regimens with different dosing schedules
2. Do not omit carboplatin radiosensitization in very high-risk Group 3 tumors with MYC amplification—this is the only subgroup where this approach demonstrated clear benefit
3. Do not use standard-dose radiation in children <3 years—chemotherapy-only approaches are mandatory to prevent severe neurocognitive sequelae
4. Do not delay bevacizumab appropriately after surgery in recurrent disease—wound healing complications can be severe

Quality of Life Considerations

Despite improved survival, long-term morbidity remains substantial. Patients require:

• Annual endocrine testing for ≥5 years (growth hormone deficiency, thyroid dysfunction)
• Neurocognitive assessment and support
• Audiologic monitoring (cisplatin-related)
• Surveillance for secondary malignancies 1

The evidence strongly supports risk-adapted, molecularly-informed dosing strategies that balance cure rates against treatment-related toxicity, with particular attention to age-appropriate modifications for very young children.